Lobbyist Public Search

Records prior to registration year 2005 are not available online. Contact the Lobbyist Division here for assistance.	Search data is collected from registration records and disclosure reports submitted by lobbyists, lobbying entities, and their clients. Massachusetts General Law requires any party providing or retaining lobbying services to register annually, and submit disclosure reports twice a year.
	Your comments are welcome: submit feedback

Disclosure reporting details

Back to search detail summary

Lobbyist disclosure reporting period: 01/01/2021 - 06/30/2021

Lobbyist name	Geoffrey Gallo
Business name	AstraZeneca Pharmaceuticals LP
Address	701 Pennsylvania Avenue NW Suite 500
City, state, zip code	Washington, DC 20004
Country	US
Agent type	Both
Phone	603-772-1559

Operating Expenses

Date	Recipient	Type of expense	Amount
06/30/2021	US Postal Service	Postage, shipping, delivery	$24.00
06/30/2021	Verizon Wireless	Advertising expenses	$450.00
		Total operating expenses	$474.00

Activities, Bill Numbers and Titles

Client: AstraZeneca Pharmaceuticals LP

Total amount paid by client; lobbyist is unable to report compensation at activity level: $19,200.00

House / Senate	Bill Number or Agency Name	Bill title or activity	Agent position	Amount	Direct business association
House Bill	1311	An Act relative to step therapy and patient safety	Support	$0.00	N/A
Senate Bill	697	An Act relative to insurance coverage for mammograms and breast cancer screening	Neutral	$0.00	N/A
House Bill	4001	An Act making appropriations for the fiscal year 2022 for the maintenance of the departments, boards, commissions, institutions and certain activities of the Commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements	Oppose	$0.00	N/A
Executive	Other	Engaged in the Health Policy Commission (HPC) Drug Pricing Review Process and the Standard Reporting Form. Specifically the process for determining valuation of Rx drugs, transparency reporting requirements and rebate negotiations.	Oppose	$0.00	N/A
Senate Bill	785	An Act to improve the accessibility and affordability of pharmaceutical drugs of public health concern	Oppose	$0.00	N/A
Senate Bill	644	An Act relative to consumer deductibles	Support	$0.00	N/A
Senate Bill	804	An Act to promote transparency and prevent price gouging of pharmaceutical drug prices	Oppose	$0.00	N/A
House Bill	1053	An Act relative to consumer deductibles	Support	$0.00	N/A
Senate Bill	790	An Act to define modest meals and refreshments in prescriber education settings	Oppose	$0.00	N/A
House Bill	1191	An Act to help patients and reduce health care costs by ensuring patient adherence to medications	Support	$0.00	N/A
House Bill	1175	An Act relative to the diagnosis and treatment of breast cancer	Neutral	$0.00	N/A
Senate Bill	696	An Act to help patients and reduce healthcare costs by ensuring patient adherence to medications	Support	$0.00	N/A
House Bill	1247	An Act to ensure more affordable care	Neutral	$0.00	N/A
House Bill	1254	An Act relative to promoting comprehensive transparency in the pharmaceutical industry	Oppose	$0.00	N/A
Senate Bill	771	An Act relative to pharmaceutical access, costs and transparency	Oppose	$0.00	N/A
Executive	Other	Engaged in discussions with members of the Executive and Legislative branches concerning the development and potential rollout of AstraZeneca’s COVID-19 vaccine. As of the filing of this report, AstraZeneca’s vaccine has yet to be approved by the Food & Drug Administration (FDA). Thus, these discussions were for planning purposes only in the event the vaccine was approved. Specifically on COVID vaccine, members of the Legislative House COVID-19 Working Group. These topics pertained to the progress of clinical trials, distribution, and supply. Engaged on various COVID-19 current Executive Orders to ensure compliance with our essential workers in MA. Specifically Executive Orders pertaining to stay-at-home advisory, business capacities and early closures and capacities and face coverings. Engaged in discussions related to the proposed rules for 101 CMR 801.00 and proposed drug pricing review regulations 958 CMR 12.00.	Neutral	$0.00	HPC Board Members, HPC Staff to include Executive Director, and the staff from CHIA
Senate Bill	756	An Act relative to step therapy and patient safety	Support	$0.00	N/A
Senate Bill	728	An Act relative to pharmaceutical gag clauses	Neutral	$0.00	N/A
Senate Bill	3	An Act making appropriations for the fiscal year 2022 for the maintenance of the departments, boards, commissions, institutions and certain activities of the Commonwealth, for interest, sinking fund and serial bond requirements and for certain permanent improvements	Oppose	$0.00	N/A
Executive	Other	Promoted and assisted with information pertaining to the Health Policy Commission (HPC) study on the use of prescription drug coupons and vouchers. Interactions (virtual) with the HPC and participation in the HPC Advisory Council quarterly meetings (virtually). Participate in public meetings/discussions pertaining to drug costs (net and gross) and value-based contracts with health plans as well as MassHealth. Promoted the overall clinical value of prescription medicines and the economic impact of the biotechnology sector in the Commonwealth of MA.	Support	$0.00	N/A
House Bill	1201	An Act ensuring access to medications	Support	$0.00	N/A
Senate Bill	1481	An Act to restore integrity in the marketing of pharmaceutical products and medical devices	Oppose	$0.00	N/A
House Bill	1137	An Act relative to cancer patient access to biomarker testing to provide appropriate therapy	Support	$0.00	N/A
Senate Bill	1465	An Act to reduce healthcare costs by promoting non-biased prescriber education	Oppose	$0.00	N/A
House Bill	2377	An Act to permit the wholesale importation of prescription drugs into the Commonwealth	Oppose	$0.00	N/A
Senate Bill	808	An Act relative to cancer patient access to biomarker testing to provide appropriate therapy	Support	$0.00	N/A
Senate Bill	1480	An Act to prevent undue influence on prescriber behavior	Oppose	$0.00	N/A
House Bill	1237	An Act relative to non-medical switching	Support	$0.00	N/A
Senate Bill	1915	An Act to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing	Oppose	$0.00	N/A
			Total amount	$0.00

Meals, Travel, and Entertainment Expenses

No meals, travel, or entertainment expenses were filed for this disclosure reporting period.

Additional Expenses

Date from	Date to	Recipient name	Expense	Amount
02/10/2021	02/10/2021	Greater Boston Chamber of Commerce Government Affairs Forum (virtual)	registration fee	$25.00
05/19/2021	05/19/2021	Greater Boston Chamber of Commerce Annual Meeting (virtual)	registration fee	$100.00
			Total amount	$125.00

Campaign Contributions

Date	Recipient name	Office sought	Amount
02/05/2021	Aaron Michlewitz	State Senate	$200.00
02/15/2021	Jon Santiago	State Representative	$200.00
02/19/2021	Mike Rodrigues	State Senate	$200.00
03/15/2021	Marjorie Decker	State Representative	$200.00
04/01/2021	Karen Spilka	State Senate	$200.00
04/05/2021	Julian Cyr	State Senate	$200.00
04/05/2021	Joe Boncore	State Senate	$200.00
04/21/2021	Tim Whelan	State Representative	$200.00
04/26/2021	Tom Stanley	State Representative	$200.00
04/27/2021	John Lawn	State Representative	$200.00
05/19/2021	Barry Finegold	State Senate	$200.00
05/25/2021	Kate Hogan	State Representative	$200.00
		Total contributions	$2,400.00

Close this page

Connect with Us